These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30977300)

  • 1. Influence of disease duration and socioeconomic factors on the prevalence of infection and hospitalization in rheumatoid arthritis: KRAC study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2019 Jul; 22(7):1216-1225. PubMed ID: 30977300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2018 Nov; 21(11):1977-1985. PubMed ID: 27452347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced incidence of extra-articular manifestations of RA through effective disease control: Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2017 Nov; 20(11):1694-1703. PubMed ID: 27943575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk of opportunistic infection in early rheumatoid arthritis.
    Kim H; Cho SK; Lee J; Bae SC; Sung YK
    Int J Rheum Dis; 2019 Jul; 22(7):1239-1246. PubMed ID: 31090187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in Hospitalizations for Serious Infections in Patients With Rheumatoid Arthritis in the US Between 1993 and 2013.
    Jinno S; Lu N; Jafarzadeh SR; Dubreuil M
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):652-658. PubMed ID: 28732148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidities and related factors in rheumatoid arthritis patients of south India- Karnataka Rheumatoid Arthritis Comorbidity (KRAC) study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Reumatismo; 2017 Aug; 69(2):47-58. PubMed ID: 28776358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type.
    Schau T; Gottwald M; Arbach O; Seifert M; Schöpp M; Neuß M; Butter C; Zänker M
    J Rheumatol; 2015 Nov; 42(11):2029-37. PubMed ID: 26373561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
    Pamuk ÖN; Kalyoncu U; Aksu K; Omma A; Pehlivan Y; Çağatay Y; Küçükşahin O; Dönmez S; Çetin GY; Mercan R; Bayındır Ö; Çefle A; Yıldız F; Balkarlı A; Kılıç L; Çakır N; Kısacık B; Öksüz MF; Çobankara V; Onat AM; Sayarlıoğlu M; Öztürk MA; Pamuk GE; Akkoç N
    Rheumatol Int; 2016 Jul; 36(7):945-53. PubMed ID: 27221456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of rheumatoid arthritis treatments and the risk of serious infections.
    Grijalva CG; Kaltenbach L; Arbogast PG; Mitchel EF; Griffin MR
    Rheumatology (Oxford); 2010 Jan; 49(1):82-90. PubMed ID: 19906833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary tract infections in patients with rheumatoid arthritis.
    Puntis D; Malik S; Saravanan V; Rynne M; Heycock C; Hamilton J; Kelly CA
    Clin Rheumatol; 2013 Mar; 32(3):355-60. PubMed ID: 23238605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis.
    Schenfeld J; Iles J; Trivedi M; Accortt NA
    Rheumatol Int; 2017 Jul; 37(7):1075-1082. PubMed ID: 28255642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing guideline-based care quality for inflammatory bowel disease and rheumatoid arthritis patients within a medical home.
    Caldera F; Saha S; Wald A; Cooley DM; Zhao YQ; Li Z; Bartels CM
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):759-66. PubMed ID: 27029237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.